BNT162B2 Omicron (LP.8.1) is an mRNA vaccine used to prevent COVID-19 caused by SARS-CoV-2. It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.
- Mechanism
- Curator reviewed · 5 references
The nucleoside-modified messenger RNA in raxtozinameran encodes for the viral spike (S) protein of SARS-CoV-2 Omicron variant lineage LP.8.1. It recognizes and binds to the host cell receptor ACE-2, allowing the virus to attach to and enter host cells. The mRNA is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length S with two point mutations within the central helix which serve to lock the S protein in an antigenically preferred prefusion conformation. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease.
- Primary indication
- BNT162B2 Omicron (LP.8.1), as the active ingredient in the 2025-2026 formulation of Comirnaty, is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in patients...Curator reviewed · 2 structured indications
- First approval
- United States, 2025
- Brand names
Resolves to
What you can answer from here — as of September 10, 2025
Which other approved drugs treat the same conditions as BNT162B2 Omicron (LP.8.1), and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account